CFO LaDuane buys 2,000 ZVRA shares at $6.77; prior 4 buys all well-timed at 90d; cluster pattern with 2 other insiders.
Clifton R. LaDuane, CFO & Treasurer, purchased 2,000 shares at $6.77 on 2024-07-17, increasing his position by 12.1% to 18,469 shares. His prior 4 open-market buys at ZVRA achieved a 100% success rate on the 90-day timing metric, with all trades followed by positive subsequent returns. The transaction coincides with a broader cluster pattern: 2 other insiders also bought within the past 14 days. Stock has appreciated 44.8% over 30 days and 46.4% over 90 days since the buy date, and currently trades at $6.59, down 6.9% from its 52-week high of $7.08. The company reported quarterly revenue of $3.4M with net losses of $16.6M, though annual revenue growth reached 162.6% year-over-year. The convergence of consistent insider buy timing at this ticker, recent multi-insider buying cluster, and strong post-buy price performance relative to historical patterns warrants attention to whether this reflects material non-public information or conviction about recovery trajectory in an unprofitable but rapidly growing biotech.